diagnostic testing

The pharma giant will also pay $55 million to fund the point-of-care diagnostics platform until the acquisition closes, which is expected to occur by mid-2024.

PreciseMDX said its new platform would allow for easier scheduling, care coordination and results reporting.

The new capital will be used to accelerate Cue’s growth.   

Alongside step-by-step instructions, the Ellume COVID-19 Home Test's accompanying app automatically reports users' results to the relevant public health authorities.

The Cue Health Monitoring System can deliver its results through a smartphone dashboard, and is intended for use by health professionals and consumers alike.

The startup, which specializes in a range of at-home testing kits, so far only offers a COVID-19 testing product for point-of-care providers.

Nurx, Carbon Health and Everlywell have officially halted their mail-order testing-kit services. But at least one startup is still moving to secure an Emergency Use Authorization for its at-home rapid serology diagnostic.

[Since this article was published, the FDA has released an alert warning that it has not yet authorized any COVID-19 home testing kits]